Coeptis Therapeutics, Inc. (COEP)
USD 9.75
(2.85%)
USD 9.75
(2.85%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -244.9 Thousand USD | 88.25% |
| 2022 | -2.08 Million USD | -209.61% |
| 2021 | 1.9 Million USD | 0.92% |
| 2020 | 1.88 Million USD | 1138.92% |
| 2019 | 152.13 Thousand USD | 145.1% |
| 2018 | 62.07 Thousand USD | 0.0% |
| 2005 | 496.44 Thousand USD | 424.69% |
| 2004 | 94.61 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 1.39 Million USD | 670.99% |
| 2024 Q2 | 229.59 Thousand USD | -83.58% |
| 2023 FY | -244.9 Thousand USD | 88.25% |
| 2023 Q3 | -411.03 Thousand USD | 66.0% |
| 2023 Q4 | -244.9 Thousand USD | 40.42% |
| 2023 Q2 | -1.2 Million USD | -194.44% |
| 2023 Q1 | -410.54 Thousand USD | 80.31% |
| 2022 Q3 | -3.53 Million USD | -334.26% |
| 2022 FY | -2.08 Million USD | -209.61% |
| 2022 Q4 | -2.08 Million USD | 41.07% |
| 2022 Q1 | 1.55 Million USD | -18.07% |
| 2022 Q2 | 1.51 Million USD | -3.09% |
| 2021 Q1 | 992.4 Thousand USD | 20197.39% |
| 2021 FY | 1.9 Million USD | 0.92% |
| 2021 Q4 | 1.9 Million USD | -44.3% |
| 2021 Q3 | 3.41 Million USD | 3148.82% |
| 2021 Q2 | 105.11 Thousand USD | -89.41% |
| 2020 FY | 1.88 Million USD | 1138.92% |
| 2020 Q4 | -4938.00 USD | -209.98% |
| 2020 Q3 | -1593.00 USD | 0.0% |
| 2019 FY | 152.13 Thousand USD | 145.1% |
| 2018 FY | 62.07 Thousand USD | 0.0% |
| 2005 FY | 496.44 Thousand USD | 424.69% |
| 2005 Q4 | 496.44 Thousand USD | 30.15% |
| 2005 Q2 | 381.43 Thousand USD | 303.0% |
| 2005 Q3 | 381.43 Thousand USD | 0.0% |
| 2005 Q1 | 94.64 Thousand USD | 0.03% |
| 2004 Q3 | -383.00 USD | 0.0% |
| 2004 Q4 | 94.61 Thousand USD | 24804.18% |
| 2004 FY | 94.61 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -18595.267% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 104.336% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 100.572% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 1.888% |
| Rebus Holdings, Inc. | 305 Thousand USD | 180.298% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 96.115% |
| Qrons Inc. | 351.42 Thousand USD | 169.69% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 139.351% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 100.564% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -1100.059% |
| Skye Bioscience, Inc. | -5.72 Million USD | 95.719% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 101.554% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 105.947% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 160.945% |
| SQZ Biotechnologies Company | -36.23 Million USD | 99.324% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 110.923% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 126.414% |
| Mesoblast Limited | 55.85 Million USD | 100.438% |
| Marizyme, Inc. | 18.56 Million USD | 101.319% |
| Genus plc | 190.6 Million USD | 100.128% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 110.954% |
| Pharming Group N.V. | 109.8 Million USD | 100.223% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 128.47% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 120.176% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 136.016% |
| ContraFect Corporation | -6.02 Million USD | 95.936% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 281.9% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 121.196% |
| IMV Inc. | 7.67 Million USD | 103.193% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 104.451% |
| MultiCell Technologies, Inc. | 90.04 USD | 272099.112% |
| ONE Bio Corp. | 9.04 Million USD | 102.709% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 66.633% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 101.892% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 117.903% |
| Q BioMed Inc. | 4.06 Million USD | 106.032% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 100.802% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 124.303% |
| Biomind Labs Inc. | 711.4 Thousand USD | 134.426% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 100.405% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 112.249% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 101.912% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 168.085% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 275.18% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 1332.738% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 111.122% |
| GB Sciences, Inc. | 1.74 Million USD | 114.016% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -33.256% |
| HST Global, Inc. | 96.79 Thousand USD | 353.022% |
| CSL Limited | 10.52 Billion USD | 100.002% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 218.762% |
| Halberd Corporation | 144.72 Thousand USD | 269.228% |
| Enzolytics Inc. | 981.65 Thousand USD | 124.948% |
| Agentix Corp. | 37.63 Thousand USD | 750.814% |
| Resverlogix Corp. | 6.45 Million USD | 103.796% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 63.614% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.988% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 99.479% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 103.464% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 109.042% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 97.23% |
| AVAX Technologies, Inc. | -5.9 Million USD | 95.851% |
| Zenith Capital Corp. | 10.06 Thousand USD | 2533.506% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.977% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 222.19% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 110.264% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 248.872% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -1236.98% |
| Kadimastem Ltd | -253.1 Thousand USD | 3.237% |
| Helix BioMedix, Inc. | -2.57 Million USD | 90.471% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 101.208% |
| BioStem Technologies, Inc. | 4.47 Million USD | 105.476% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 221.691% |
| LadRx Corporation | -2.03 Million USD | 87.974% |
| Cell Source, Inc. | 9.23 Million USD | 102.653% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 138.558% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 138.558% |
| NovAccess Global Inc. | 2.17 Million USD | 111.242% |
| Affymax, Inc. | -5.59 Million USD | 95.624% |
| Itoco Inc. | 228.3 Thousand USD | 207.272% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 280.094% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 104.941% |
| Mobile Lads Corp. | 484.23 Thousand USD | 150.577% |
| CytoDyn Inc. | 20.26 Million USD | 101.209% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -37752.859% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -2542.415% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 103.178% |
| SYBLEU INC | 473.71 Thousand USD | 151.7% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 105.495% |
| International Stem Cell Corporation | 2.59 Million USD | 109.456% |
| Bioxytran, Inc. | 1.89 Million USD | 112.897% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 492.399% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 111.23% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 107.132% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 102.863% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 131.699% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 80.407% |
| Neutra Corp. | 52.18 Thousand USD | 569.289% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 90.16% |
| PureTech Health plc | -167.19 Million USD | 99.854% |
| IXICO plc | -4.44 Million USD | 94.49% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 101.853% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 100.446% |
| CSL Limited | 10.52 Billion USD | 100.002% |
| Cellectis S.A. | -43.81 Million USD | 99.441% |